Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

7 treatments under study, led by Exercise

Research Leaders

7 sponsors active, led by Chang Gung Memorial Hospital

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 1 (1)

Trial Status

Not Yet Recruiting1
Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT07831473Phase 1Not Yet Recruiting

Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults

NCT07035743Recruiting

Bronchial Response to Exercise After Double Lung Transplantation

NCT01241201Not ApplicableCompleted

Intestinal Barrier Function and Probiotics.

Showing all 3 trials

Research Network

Common Treatments

  • Exercise1
  • Vlpden02 10 Μg 25 Μg Of Each Vlp Alfq Adjuvant1
  • Priobiotic Supplement Vsl31
  • Alfq Adjuvant Saline1
  • Rden3delta301

Active Sponsors

  • Chang Gung Memorial Hospital1
  • TNO1
  • VSL Pharmaceuticals1
  • Global Health Innovative Technology Fund1
  • VLP Therapeutics1

Top Investigators

Related Conditions

  • Randomised Clinical Trial1
  • Dose Escalation And Safety1
  • Double Blind1
  • Inflammation1
  • Lung Transplant Recipients1

Activity Timeline